ESMO 2019: First-Line Versus Non–First-Line Bortezomib in Asian Patients With Myeloma
Posted: Monday, October 7, 2019
According to a study presented at the European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona (Abstract 1087P), first-line treatment with bortezomib may improve clinical outcomes in Taiwanese patients with multiple myeloma compared with non–first-line treatment. This study, conducted by Ching-Liang Ho, MD, of the National Defense Medical Center, Taipei, Taiwan, and colleagues may provide stage-stratified survival and disease-specific survival rates as well. The study was simultaneously published in Annals of Oncology.
The study authors retrospectively identified 5,726 patients with newly diagnosed multiple myeloma using data from the National Health Institute Research Database; they were treated between 2007 and 2015 in Taiwan. Of these patients, 1,116 were in the control group and received bortezomib as a non–first-line drug. The case group consisted of 4,610 patients who received first-line bortezomib.
The clinical outcomes of patients treated with first-line bortezomib were better than those of patients who received bortezomib as a non–first-line drug. The proportion of future hospital deaths in the treatment group was 15.7% (702 of 4,464) versus 19.8% (221 of 1,116) in the control group. The probability of hospital death risk was 0.387 times higher in patients who received first-line bortezomib with and without bone marrow transplantation than in patients treated with non–first-line bortezomib without bone marrow transplantation.
Disclosure: The study authors reported no conflicts of interest.
